Comparison of the Efficacy and Safety of Entecavir Versus Adefovir in Subjects Chronically Infected With Hepatitis B Virus and Evidence of Hepatic Decompensation
Interventional
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment
Change From Baseline in Hepatitis B Virus (HBV) DNA by Polymerase Chain Reaction (PCR) at Week 24
Mean reduction in serum HBV DNA determined by PCR assay (log10 copies/mL) at Week 24 adjusted for baseline HBV DNA and lamivudine resistance (LVDr) status, based on linear regression analysis.
Baseline, Week 24
No
Bristol-Myers Squibb
Study Director
Bristol-Myers Squibb
United States: Food and Drug Administration
AI463-048
NCT00065507
August 2003
May 2013
Name | Location |
---|---|
Johns Hopkins University | Baltimore, Maryland 21205 |
Mount Sinai Medical Center | New York, New York 10029 |
Baylor University Medical Center | Dallas, Texas 75246 |
McGuire DVAMC | Richmond, Virginia 23249 |
California Pacific Medical Center | San Francisco, California 94115 |
Yale University School Of Medicine | New Haven, Connecticut 06520 |
University of Miami School of Medicine | Miami, Florida 33136 |
Research And Education, Inc. | San Diego, California 92115 |
Pediatric Gasteroenterology | Atlanta, Georgia 30342 |
Hawaii Medical Center East | Honolulu, Hawaii 96817 |
Indiana University Med Center | Indianapolis, Indiana 46202 |
The Cht Liver Research Center | Louisville, Kentucky 40292 |
Henry Ford Health System Irb | Detroit, Michigan 48202 |
Columbia Presbyterian Medical Center (Cpmc) | New York, New York 10032 |
Integris Baptist Medical Center | Oklahoma City, Oklahoma 73112 |
Ut Southwestern Medical Center | Dallas, Texas 75390 |